Aurinia Pharmaceuticals Q2 2026 Earnings Report

Aurinia Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.24
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Aurinia Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $80.45 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Aurinia Pharmaceuticals Announcement Details

• Quarter: Q2 2026
• Date: 8/3/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Aurinia Pharmaceuticals (NASDAQ:AUPH). is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S. Food and Drug Administration for the treatment of adult patients with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus. Beyond lupus nephritis, Aurinia is investigating voclosporin in additional indications such as focal segmental glomerulosclerosis (FSGS) and dry eye disease, with several ongoing clinical trials to evaluate safety and efficacy.

Founded in the early 1990s, Aurinia is headquartered in Victoria, British Columbia, and maintains a presence in North America to support its clinical and commercial activities. The company’s leadership team comprises experienced professionals in drug development, regulatory affairs and commercial operations, guiding Aurinia through pivotal clinical milestones and into its initial product launch. As Aurinia continues to expand its pipeline and explore partnerships, it remains committed to addressing unmet needs in autoimmune disease management.